Last updated on November 2017

Diabetes (Type 2 ), taking METFORMIN


Brief description of study

Diabetes (Type 2 ), taking METFORMIN

Detailed Study Description

Merck is conducting a clinical research study for adults who are at least 25 years of age and have been diagnosed with type 2 diabetes. The purpose of this study is to compare the safety and effectiveness of the oral medications sitagliptin versus dapagliflozin for the treatment of type 2 diabetes as an add-on to metformin. The use of these medications combined with metformin is investigational.

Approximately 550 volunteers around the world will participate in this clinical research study.

The study medication will be provided to study participants at no charge. Nutrition and exercise counseling will also be provided.

The purpose of the study is to assess the effect of the addition of sitagliptin to metformin compared with the addition of dapagliflozin to metformin on hemoglobin A1c (A1C) over 24 weeks of treatment

7 VISITS TOTAL

ClinicalTrials.gov identifier: NCT02532855

Clinical Study Identifier: TX8709

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Richard Menzies

Virginia Research Center
Midlothian, VA USA
  Connect »